Regulatory overbilling settlement puts Humana in focus

Humana (HUM) is under closer investor scrutiny after The Villages Health, which it acquired in 2025, agreed to a US$541.5m settlement over alleged Medicare Advantage overbilling using false diagnosis codes.

The overbilling was self disclosed before The Villages Health entered bankruptcy, and the government will recover funds through the bankruptcy estate while insurers return credited overpayments. For Humana shareholders, the case raises questions about regulatory risk, compliance oversight and how inherited liabilities from acquisitions might influence future capital allocation priorities.

Humana shares trade at US$392.63. The stock has a strong 90 day share price return of 28.55% and a year to date share price return of 48.45%, while the 1 year total shareholder return of 33.71% contrasts with weaker 3 and 5 year total shareholder returns. This signals recent momentum alongside a mixed longer term record as investors weigh regulatory headlines against the broader business story.

Spot potential counterparts to Humana's recent momentum and regulatory focus by scanning our hand picked 76 resilient stocks with low risk scores in similarly scrutinized sectors.

After a sharp move to US$392.63 driven by both momentum and Medicare scrutiny, Humana now leaves you balancing fear of overpaying against fear of missing further upside. So how does the current valuation stack up against those risks?

Most Popular Narrative: 27.3% Overvalued

The most followed Humana narrative pegs fair value at $308.33 compared with the current $392.63 share price. This sets a clear valuation gap for you to assess.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $183.5 billion, earnings will come to $2.9 billion, and it would be trading on a PE ratio of 15.9x, assuming you use a discount rate of 7.1%.

We always encourage you to reach your own conclusions. Sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable. Read the complete narrative.

If you want to see what justifies that gap between price and fair value, the narrative leans on compounding revenue, rising margins and a reset profit multiple that may surprise you.

Result: Fair Value of $308.33 (OVERVALUED)

However, you still need to watch for Medicare Advantage Stars outcomes and any shifts in medical cost trends, as these could quickly challenge this Humana valuation story.

Another view on Humana's valuation

The first Humana narrative leans on analyst targets that suggest the stock is 27.3% above fair value. Yet Simply Wall St's DCF model paints a very different picture, with an estimated future cash flow value of $1,001.10 per share versus the current $392.63 price, which screens as materially undervalued.

That gap between analyst targets and the DCF result reflects very different views on how sustainable Humana's cash generation will be in the face of Medicare scrutiny and Stars risk. The question for you is which set of assumptions feels more realistic for the next decade.

Next Steps

With Humana facing both regulatory questions and valuation debate, it makes sense to review the data yourself and decide quickly what you think. To see the balance of potential upside and downside that other investors are focused on, start with the 2 key rewards and 2 important warning signs.

Looking for more Humana style investment ideas?

If Humana has your attention, do not stop there. Use these focused stock lists to pressure test your thinking and spot opportunities you might otherwise overlook.

• Target potential value opportunities by checking companies that screen as quality and priced below intrinsic estimates through the 46 high quality undervalued stocks.
• Strengthen your downside protection by reviewing companies with sturdy finances using the list of solid balance sheet and fundamentals (50 results).
• Hunt for lesser known opportunities with strong fundamentals by scanning the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.